Multispecific Binding Proteins for NK Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including those for prostate, breast, and lung cancers, are often ineffective and associated with significant side effects, highlighting the need for more targeted and specific therapeutic approaches that can effectively engage the immune system to destroy cancer cells.
Innovation Solution
Development of multi-specific binding proteins that bind to the NKG2D receptor and CD16 on natural killer cells, while also targeting tumor-associated antigens such as CAIX, ANO1, mesothelin, TROP2, CEA, or Claudin-18.2 on cancer cells, to activate natural killer cells and facilitate cancer cell destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-specific binding proteins are designed to bind multiple targets simultaneously, then the ability to activate natural killer cells and destroy cancer cells is improved, but the device complexity increases
Solution Approach 1:
The patent combines multiple binding functions into a single protein molecule by fusing different antigen-binding domains (such as scFv, Fab, or single-domain antibodies) against different tumor-associated antigens (e.g., CEA, TROP2, mesothelin) and immune cell receptors (e.g., NKG2D, CD16) into one polypeptide chain or linked structure, enabling simultaneous binding to multiple targets while maintaining a manageable structural organization through modular domain architecture
Solution Approach 2:
The multi-specific binding protein is designed to perform multiple functions simultaneously: binding to tumor-associated antigens for target recognition, binding to activating receptors on natural killer cells for immune activation, and potentially binding to inhibitory receptors for regulation. This multi-functional design allows a single protein to coordinate the entire immune engagement process without requiring separate molecules for each function
2Adaptability or versatility
If current cancer treatments are used, then treatment coverage is broad, but effectiveness is reduced and side effects increase
Solution Approach 1:
The patent employs tumor-associated antigens that are specifically overexpressed on cancer cells (such as CEA in gastrointestinal cancers, TROP2 in breast and lung cancers, mesothelin in mesothelioma and pancreatic cancer) rather than using non-specific targets. This localized targeting ensures that the binding proteins selectively bind to cancer cells with high antigen expression while sparing normal cells, thereby improving treatment effectiveness and reducing off-target side effects
Solution Approach 2:
The multi-specific binding protein acts as an intermediary molecule that bridges the gap between the immune system and cancer cells. By simultaneously binding to tumor-associated antigens on cancer cells and activating receptors on natural killer cells, the protein mediates the recruitment and activation of immune cells specifically at the tumor site, enhancing treatment effectiveness while maintaining broad adaptability across different cancer types through selection of appropriate antigen targets
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These proteins enhance the activity of natural killer cells, bringing them into proximity with cancer cells, thereby directly or indirectly leading to the destruction of cancer cells, offering a potentially more effective and targeted treatment for various types of cancer with reduced side effects.
Implementation Method 1
multi-specific binding proteins that bind to the NKG2D receptor and CD16 on natural killer cells, while also targeting tumor-associated antigens such as CAIX, ANO1, mesothelin, TROP2, CEA, or Claudin-18.2 on cancer cells
Implementation Method 2
These proteins enhance the activity of natural killer cells, bringing them into proximity with cancer cells, thereby directly or indirectly leading to the destruction of cancer cells
Data Source
AI summary
Multi-specific binding proteins that bind the NKG2D receptor, CD16, and a tumor-associated antigen selected from carbonic anhydrase 9 (CAIX), anoctamin-1 (ANO1), mesothelin, TROP2, CEA and claudin-18.2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.